Immunogenicity of 23-valent pneumococcal vaccine in children with systemic lupus erythematosus

Iranian Journal of Immunology

Volumn 13, Issue 3, 2016, Pages 204-219

  Alyasin, Soheila ^a   Adab, Marzieh ^b   Hosseinpour, Asieh ^b   Amin, Reza ^a   Babaei, Maryam ^b  

^a Division of Clinical Immunology and Allergy   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

23 Valent Pneumococcal Vaccine; Anti Pneumococcal Antibody; Children; Immunogenicity; Systemic Lupus Erythematosus (SLE)

Indexed keywords

23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; BACTERIUM ANTIBODY; PNEUMOCOCCUS VACCINE;

ADOLESCENT; BLOOD; CASE CONTROL STUDY; CHILD; COMPLICATION; DRUG EFFECTS; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADOLESCENT; ANTIBODIES, BACTERIAL; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNITY, HUMORAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 85015593840     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Grammer AC, Lipsky PE. B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther. 2003; 5:22S-27S.
2. Azevedo PC, Murphy G, Isenberg DA. Pathology of systemic lupus erythematosus: the challenges ahead. Methods Mol Biol. 2014; 1134:1-16.
3. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J ClinPathol. 2003; 56:481-90.
4. Jeurissen A, Moens L, Raes M, Wuyts G, Willebrords L, Sauer K, et al. Laboratory Diagnosis of Specific Antibody Deficiency to Pneumococcal Capsular Polysaccharide Antigens. Clin Chem. 2007; 53: 505-10.
5. Sorensen RU, Harvey T, Levia LE. Selective antibody deficiency with normal immunoglobulins, Immunodeficiency, In: KrassimirMetodiev (Editor), Immunodeficiency,1st ed. InTech; 2012.
6. Doria A, Canova M, Tonon M, Zen M, Rampudda E, Bassi N, et al. Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev.2008; 8: 24-8.
7. Gluck T, Muller-Ladner U. Vaccination in patients with Chronic Rheumatic or Autoimmune Disease. Clin Infect Dis. 2008; 46: 1459-65.
8. Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for person aged 0 through 18 years and adults aged 19 years and older--United States. MMWR Surveill Summ. 2013; 62: 1S-19S.
9. Klippel JH, Karsh J, Stahl NI, Decker JL, Steinberg AD, Schiffman G. A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus. Arthritis Rheum. 1979; 22: 1321-5.
10. Jarrett MP, Schiffman G, Barland P, Grayzel Al. Impaired response to pneumococcal vaccine in systemic lupus erytheatosus. Arthritis Rheum. 1980; 23: 1287-93.
11. Salemi S, D'Amelio R. Are anti-infectious vaccinations safe and effective in patients with autoimmunity? Int Rev Immunol. 2010; 29: 270-314.
12. Conti F, Rezai S, Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmun Rev. 2008; 8: 124-8.
13. Miyamoto M, Ono E, Barbosa C, Terreri M, Hilário M, Salomão R, et al. Vaccine antibodies and T-and B-cell interaction in juvenile systemic lupus erythematosus. Lupus. 2011; 20: 736-44.
14. Aron-Maor A, Shoenfeld Y. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas. Lupus. 2001; 10: 237-40.
15. Maillefert JF, Sibilia J, Toussirot E, Vignon E, Eschard JP, Lorcerie B, Juvin R, et al. Rheumatic disorders developed after hepatitis B vaccination. Rheumatology. 1999; 38: 978-83.
16. Kashef S, Ghazizadeh F, Derakhshan A, Farjadian Sh, Alyasin S. Antigen-SpecificAntibody Response in Juvenile-Onset SLE Patient Following Routine Immunization with Tetanus Toxoid. Iran J Immunol. 2008; 5: 181-4.
17. Battafarano DF, Battafarano NJ, Larsen L, Dennis Dyer P, Older SA, Muehlbauer S, et al. Antigen-Specific Antibody Response In Lupus Patients Following Immunization. Arthritis Rheum. 1998; 41: 1828-34.
18. Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. Immunogenicity and Safety of Pneumococcal Vaccination in Patient with Rheumatoid Arthritis or Systemic Lupus Erythematosus. Clin Infect Dis. 2002; 34: 147-53.
19. Elkayam O, Ablin J, Caspi D. Safety and efficacy of vaccination against streptococcus pneumonia in patient with rheumatic disease. Autoimmune Rev. 2007; 6: 312-4.
20. Tarján P, Sipka S, Maródi L, Nemes E, Lakos G, Gyimesi E, et al. No short-term immunological effects of Pneumococcus vaccination in patients with systemic lupus erythematosus. Scand J Rheumatol. 2002; 31:211-5.
21. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum. 1997; 40:1725.
22. Lee HJ, Kang JH, Henrichsen J, Konradsen HB, Jang SH, Shin HY, et al. Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in healthy children and in children at increased risk of pneumococcal infection. Vaccine. 1995; 13:1533-8.
23. Rose MA, Schubert R, Kujumdshiev S, Kitz R, Zielen S. Immunoglobulins and immunogenicity of pneumococcal vaccination in preschool asthma. Int J Clin Pract. 2006; 60: 1425-31.
24. Zhao H, Jung JA, Briles DE, Kita H, Tsigrelis C, Juhn YJ. Asthma and antibodies to pneumococcal virulence proteins. Infection. 2013; 41: 927-34.
25. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosisstudies in SLE. Arthritis Rheum. 1992; 35: 630-40.
26. Schauer U, Stemberg F, Rieger CH, Buttner W, Borte M, Schubert S, et al. Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults. Clin Diagn Lab Immunol. 2003; 10: 202–7.
27. Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003; 10:514-9.
28. Balmer P, North J, Baxter D, Stanford E, Melegaro A, Kaczmarski E B, et al. Measurement and interpretation of pneumococcal IgG levels for clinical management. Clin Exp Immunol. 2003; 133: 364–9.
29. Aghamohammadi A, Mahmoodi M, Rezaei N, Safari Z, Heidarnasab D, Divsalar K, et al. The assessment of antibody response following immunization with polysaccharide vaccine in patients with chronic kidney disease. TUMJ. 2011; 69: 92-98.
30. Karimi A, Isaeian A, Aghamohammadi A, Moin M, Zandieh F, et al. Immunological evaluation of children with recurrent ear,nose, and throat (ENT) infections. Iran J Pediatr. 2007;17: 1-13.
31. Vendrell M, de Gracia J, Rodrigo MJ, Cruz MJ, Alvarez A, Garcia M, et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology. Chest. 2005; 127: 197-204.
32. Oʼdell JR, Gilg J, Palmer W, Haire C, Klassen L, Moore G. Pneumococcal vaccine in rheumatoid arthritis. J ClinRheumatol. 1996; 2:59-63.
33. De Roux, Schmidt N, Rose M, Zielen S, Pletz M, Lode H. Immunogenicity of the pneumococcal polysaccharide vaccine in COPD patients:the effect of systemic steroids. Respir Med. 2004; 98:1187–94.
34. Kapetanovic MC, Saxne T, Sjo¨holm A, Truedsson L, Jo¨nsson G, Geborek P. Influenc of methotrexate, TNF-blockers and prednisolone on antibody responses to pneumococcal vaccine in patients with rheumatoid arthritis. Rheumatology. 2006; 45:106–11.
35. Sorensen RU, Leiva LE, Javier FC 3rd, Sacerdote DM, Bradford N, Butler B, et al. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol. 1998; 102:215-21.